155 related articles for article (PubMed ID: 35325018)
1. Identification of deleterious variants of uncertain significance in BRCA2 BRC4 repeat through molecular dynamics simulations.
Sinha S; Qin Z; Tam B; Wang SM
Brief Funct Genomics; 2022 May; 21(3):202-215. PubMed ID: 35325018
[TBL] [Abstract][Full Text] [Related]
2. Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
Hu C; Susswein LR; Roberts ME; Yang H; Marshall ML; Hiraki S; Berkofsky-Fessler W; Gupta S; Shen W; Dunn CA; Huang H; Na J; Domchek SM; Yadav S; Monteiro ANA; Polley EC; Hart SN; Hruska KS; Couch FJ
Clin Cancer Res; 2022 Sep; 28(17):3742-3751. PubMed ID: 35736817
[TBL] [Abstract][Full Text] [Related]
3.
Khan MA; Varma AK
J Biomol Struct Dyn; 2023 Nov; 41(19):9879-9889. PubMed ID: 36404616
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Identification of Deleterious
Tam B; Sinha S; Qin Z; Wang SM
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768775
[TBL] [Abstract][Full Text] [Related]
5. Preomic profile of BxPC-3 cells after treatment with BRC4.
Previtali V; Myers SH; Poppi L; Wynne K; Casamassima I; Girotto S; Di Stefano G; Farabegoli F; Roberti M; Oliviero G; Cavalli A
J Proteomics; 2023 Sep; 288():104983. PubMed ID: 37536521
[TBL] [Abstract][Full Text] [Related]
6. BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair.
Jimenez-Sainz J; Mathew J; Moore G; Lahiri S; Garbarino J; Eder JP; Rothenberg E; Jensen RB
Elife; 2022 Sep; 11():. PubMed ID: 36098506
[TBL] [Abstract][Full Text] [Related]
7. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
Tram E; Savas S; Ozcelik H
PLoS One; 2013; 8(5):e62468. PubMed ID: 23704879
[TBL] [Abstract][Full Text] [Related]
8. Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules.
Jimenez-Sainz J; Jensen RB
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065235
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated mutations in BRC domains of BRCA2 affect homologous recombination induced by Rad51.
Tal A; Arbel-Goren R; Stavans J
J Mol Biol; 2009 Nov; 393(5):1007-12. PubMed ID: 19747923
[TBL] [Abstract][Full Text] [Related]
10. High levels of BRC4 induced by a Tet-On 3G system suppress DNA repair and impair cell proliferation in vertebrate cells.
Abe T; Branzei D
DNA Repair (Amst); 2014 Oct; 22():153-64. PubMed ID: 25218467
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.
Guidugli L; Shimelis H; Masica DL; Pankratz VS; Lipton GB; Singh N; Hu C; Monteiro ANA; Lindor NM; Goldgar DE; Karchin R; Iversen ES; Couch FJ
Am J Hum Genet; 2018 Feb; 102(2):233-248. PubMed ID: 29394989
[TBL] [Abstract][Full Text] [Related]
12. A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.
Guidugli L; Pankratz VS; Singh N; Thompson J; Erding CA; Engel C; Schmutzler R; Domchek S; Nathanson K; Radice P; Singer C; Tonin PN; Lindor NM; Goldgar DE; Couch FJ
Cancer Res; 2013 Jan; 73(1):265-75. PubMed ID: 23108138
[TBL] [Abstract][Full Text] [Related]
13. Classification of MLH1 Missense VUS Using Protein Structure-Based Deep Learning-Ramachandran Plot-Molecular Dynamics Simulations Method.
Tam B; Qin Z; Zhao B; Sinha S; Lei CL; Wang SM
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255924
[TBL] [Abstract][Full Text] [Related]
14. Classification of VUS and unclassified variants in
Sinha S; Wang SM
Comput Struct Biotechnol J; 2020; 18():723-736. PubMed ID: 32257056
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain.
Hu C; Huang H; Na J; Lumby C; Abozaid M; Holdren MA; Rao TJ; Karam R; Pesaran T; Weyandt JD; Csuy CM; Seelaus CA; Young CC; Fulk K; Heidari Z; Morais Lyra PC; Couch RE; Persons B; Polley EC; Gnanaolivu RD; Boddicker NJ; Monteiro ANA; Yadav S; Domchek SM; Richardson ME; Couch FJ
Am J Hum Genet; 2024 Mar; 111(3):584-593. PubMed ID: 38417439
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and characterization of BRC4 mutants based on the crystal structure of BRC4-RAD51(191-220).
Zhao D; Lu K
J Mol Model; 2015 Nov; 21(11):299. PubMed ID: 26522863
[TBL] [Abstract][Full Text] [Related]
17. Interrogation of the protein-protein interactions between human BRCA2 BRC repeats and RAD51 reveals atomistic determinants of affinity.
Cole DJ; Rajendra E; Roberts-Thomson M; Hardwick B; McKenzie GJ; Payne MC; Venkitaraman AR; Skylaris CK
PLoS Comput Biol; 2011 Jul; 7(7):e1002096. PubMed ID: 21789034
[TBL] [Abstract][Full Text] [Related]
18. Sequence fingerprints in BRCA2 and RAD51: implications for DNA repair and cancer.
Lo T; Pellegrini L; Venkitaraman AR; Blundell TL
DNA Repair (Amst); 2003 Sep; 2(9):1015-28. PubMed ID: 12967658
[TBL] [Abstract][Full Text] [Related]
19. BRCA2 BRC motifs bind RAD51-DNA filaments.
Galkin VE; Esashi F; Yu X; Yang S; West SC; Egelman EH
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8537-42. PubMed ID: 15937124
[TBL] [Abstract][Full Text] [Related]
20. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
